Bristol Myers Squibb Company $BMY Shares Bought by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its holdings in Bristol Myers Squibb by **3.7%**, acquiring an additional **14,918 shares**, resulting in **413,438 shares** valued at **$19.14 million**.
• Despite strong quarterly earnings, analysts have recently downgraded Bristol Myers Squibb, with **Daiwa America** lowering its rating from "strong-buy" to "hold" and setting a price target of **$42.00**.
• Bristol Myers Squibb declared a quarterly dividend of **$0.62**, translating to an annual yield of **5.4%**, with a **100% payout ratio** indicated.

IFM Investors Pty Ltd lifted its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 413,438 shares of the biopharmaceutical company's stock after acquiring an additional 14,918 shares during the period. IFM Investors Pty Ltd's holdings in Bristol Myers Squibb were worth $19,138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in BMY. Pinney & Scofield Inc. acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter worth approximately $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb during the fourth quarter worth $26,000. Global Wealth Strategies & Associates boosted its stake in Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Bristol Myers Squibb during the first quarter worth $31,000. Finally, Accent Capital Management LLC acquired a new position in Bristol Myers Squibb during the first quarter worth $33,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Down 1.2%

Shares of Bristol Myers Squibb stock traded down $0.55 during trading hours on Friday, hitting $45.05. The company's stock had a trading volume of 28,352,566 shares, compared to its average volume of 9,937,920. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The firm has a fifty day moving average of $46.93 and a 200-day moving average of $49.66. The stock has a market cap of $91.70 billion, a price-to-earnings ratio of 18.17, a P/E/G ratio of 2.30 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company's quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.5%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb's payout ratio is currently 100.00%.

Analysts Set New Price Targets

BMY has been the topic of a number of recent research reports. Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective on the stock. in a research note on Tuesday, August 5th. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Citigroup lowered their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Hold" and an average target price of $56.38.

Insider Activity

In related news, EVP David V. Elkins sold 56,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.